Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
R-Pharm
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of solid tumor malignancy unresponsive to current treatment options
Measurable or nonmeasurable disease as defined by Response Evaluation Criteria in Solid Tumors
Lapse of at least 1 week since minor surgery and of at least 3 weeks since major surgery and radiation therapy
Eastern Cooperative Oncology Group performance status of 0-1
Lapse of at least 4 weeks since immunotherapy or chemotherapy
Negative pregnancy test result within 72 hours of study drug administration for any woman of childbearing potential (WOCBP)
You may not be if
WOCBP unable or unwilling to use birth control during study and for up to 4 weeks after study completion
Women who are pregnant or breastfeeding
Fertile men not using effective birth control with partners who are WOCBP
Gastrointestinal(GI) disease or GI tract surgery that could impact drug absorption
Inability to swallow capsules
Inability to be venipunctured or to tolerate venous access
Known symptomatic brain metastases
Common Terminology Criteria for Adverse Events Grade 2 or greater neuropathy or history of Grade 3 or greater neuropathy
Psychiatric conditions inhibiting compliance with protocol requirements
Uncontrolled medical disorder or active infection that would impair participant's ability to receive protocol therapy or whose control may be jeopardized by the study treatment protocol
Inadequate hematologic, hepatic, or renal function
History of significant drug allergy
Previous exposure to ixabepilone
Exposure to any investigational drug or placebo within 4 weeks of enrollment
Concurrent chemotherapy regimen
Use of cytochrome P4503A4 inhibitors or inducers within 2 weeks of treatment initiation (unless approved by medical monitor)
Use of steroids (except as antiemetic)
Prisoners or subjects involuntarily detained for treatment
